Editorial: Clinical Trials in Cardiovascular Medicine: 2025 — Addressing Residual Cardiovascular Risks Through Precision-Guided Approaches - Quiz - MDSpire

Editorial: Clinical Trials in Cardiovascular Medicine: 2025 — Addressing Residual Cardiovascular Risks Through Precision-Guided Approaches

  • By

  • Wang, Euscia Y

  • XU, KEMAN

  • Shao, Ying

  • Lu, Yifan

  • Hung, Shih yu

  • Yuan, Bo

  • Xiang, Haiyan

  • Wang, Hong

  • Yang, MD, PhD, Professor Xiaofeng

  • July 2, 2026

  • 0 min

Share

Original Source(s)

Editorial: Clinical Trials in Cardiovascular Medicine: 2025 — Addressing Residual Cardiovascular Risks Through Precision-Guided Approaches

  • by Wang, Euscia Y, XU, KEMAN, Shao, Ying, Lu, Yifan, Hung, Shih yu, Yuan, Bo, Xiang, Haiyan, Wang, Hong, Yang, MD, PhD, Professor Xiaofeng

  • July 2, 2026

Related Content

Gut dysbiosis and systemic inflammation in elderly hypertensive patients with amnestic mild cognitive impairment

FDA Cites Manufacturing Issues for Cytisinicline

Application supported by Phase 3 smoking-cessation data and long-term safety findings.

Can resistance training alone or resistance training combined with aerobic training improve arterial stiffness, endothelial function, and other vascular function indicators in adults with hypertension or overweight/obesity-related vascular risk? A systematic review and meta-analysis of randomized controlled trials